

1 **Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the**  
2 **diagnosis of pulmonary tuberculosis:**

3

4 **Supplementary Results**

5

6 Novel N. Chegou<sup>1</sup>, Jayne S. Sutherland<sup>2</sup>, Anna-Ritah Namuganga<sup>3</sup>, Paul LAM Corstjens<sup>4</sup>,  
7 Annemieke Geluk<sup>5</sup>, Gebremedhin Gebremichael<sup>6</sup>, Joseph Mendy<sup>2</sup>, Stephanus Malherbe<sup>1</sup>, Kim  
8 Stanley<sup>1</sup>, Gian D. van der Spuy<sup>1</sup>, Magdalena Kriel<sup>1</sup>, Andre G. Loxton<sup>1</sup>, Belinda Kriel<sup>1</sup>, Felanji  
9 Simukonda<sup>7,#</sup>, Yonas Bekele<sup>8</sup>, Jacob A Sheehama<sup>9</sup>, Josefina Nelongo<sup>9</sup>, Marieta van der Vyver<sup>9</sup>,  
10 Atsbeha Gebrexabher<sup>6</sup>, Habteyes Hailu<sup>6</sup>, Maria M. Esterhuyse<sup>10</sup>, Ida Rosenkrands<sup>11</sup>, Claus  
11 Aagard<sup>11</sup>, Martin Kidd<sup>12</sup>, Desta Kassa<sup>5</sup>, Adane Mihret<sup>8</sup>, Rawleigh Howe<sup>8</sup>, Jacqueline M. Cliff<sup>13</sup>,  
12 Amelia C. Crampin<sup>7</sup>, Harriet Mayanja Kizza<sup>2</sup>, Stefan H.E. Kaufmann<sup>10</sup>, Hazel M Dockrell<sup>13</sup>,  
13 Tom HM Ottenhoff<sup>5</sup>, and Gerhard Walzl<sup>\*1</sup> for the AE-TBC consortium

14

15 **Affiliations:**

16 <sup>1</sup>DST/NRF Centre of Excellence for Biomedical Tuberculosis Research and SAMRC Centre  
17 for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of  
18 Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000, South  
19 Africa

20 <sup>2</sup>Vaccines and Immunity, Medical Research Council Unit, Fajara, The Gambia

21 <sup>3</sup>Uganda-Case Western Research Collaboration - Makerere University, PO Box 663, Kampala,  
22 Uganda

23 <sup>4</sup>Department of Molecular Cell Biology, Leiden University Medical Centre, PO Box 9600,  
24 2300 RC Leiden, The Netherlands

25 <sup>5</sup>Department of Infectious Diseases, Leiden University Medical Centre, PO Box 9600, 2300  
26 RC Leiden, The Netherlands

27 <sup>6</sup>Ethiopian Public Health Institute, Addis Ababa, Ethiopia

28 <sup>7</sup>Karonga Prevention Study, Chilumba, Malawi

29 <sup>8</sup>Armauer Hansen Research Institute, Addis Ababa, Ethiopia

30 <sup>9</sup>School of Medicine, Faculty of Health Sciences, University of Namibia, Namibia

31 <sup>10</sup>Department of Immunology, Max Planck Institute for Infection Biology, Charitéplatz 1,  
32 10117 Berlin, Germany

33 <sup>11</sup>Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen 2300s,  
34 Denmark

35 <sup>12</sup>Centre for Statistical Consultation, Department of Statistics and Actuarial Sciences,  
36 Stellenbosch University, Cape Town, South Africa

37 <sup>13</sup>Department of Immunology and Infection, London School of Hygiene and Tropical  
38 Medicine, Keppel Street, London WC1E 7HT, UK

39 #Currently at URC Malawi Lab Project, PO Box 1921, Lilongwe, Malawi

40

41 **\*Corresponding Author:** Gerhard Walzl, DST/NRF Centre of Excellence for Biomedical  
42 Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division of Molecular  
43 Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch  
44 University, PO Box 241, Cape Town, 8000, South Africa. Telephone: +27 21 938 9124, E-  
45 mail: [gwalzl@sun.ac.za](mailto:gwalzl@sun.ac.za)

46

47 **Alternate corresponding author:** Dr Novel N Chegou, DST/NRF Centre of Excellence for  
48 Biomedical Tuberculosis Research and SAMRC Centre for Tuberculosis Research, Division  
49 of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences,  
50 Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa. Telephone: +27 21 938  
51 9953, E-mail: [novel@sun.ac.za](mailto:novel@sun.ac.za)

52

53

54

55

56

57

58

59

60

61

62 **Supplementary Table 1: Median levels of individual analytes (pg/ml) in HIV uninfected**  
63 **study participants (n=135 TB Vs. n=223 ORD) and accuracies in the diagnosis of TB**  
64 **disease as determined by area under the ROC curve.** Only analytes with p-values <0.05 in  
65 the Mann Whitney U test are shown. IQR= Inter-quartile range, AUC = area under the ROC  
66 curve,  $N$ = Unstimulated levels,  $Ag-N$  = antigen specific levels, \*The negative median values  
67 indicate that the value obtained in the antigen stimulated tube was lower than the value obtained  
68 in the nil tube and this phenomenon has been observed in previous studies<sup>1</sup>.

Analyte	TB (IQR)	ORD (IQR)	P-value	AUC (95% CI)
<b>IL-1ra<sub>N</sub></b>	386.7(200.7-646.5)	295.5(159.2-525.4)	0.04	0.59(0.51-0.67)
<b>VEGF<sub>N</sub></b>	102.8(0.0-226.0)	55.4(0.0-119.0)	0.002	0.61(0.55-0.68)
<b>IFN-<math>\gamma</math><sub>N</sub></b>	17.79(9.0-34.9)	6.1(1.9-15.30)	<0.0001	0.73(0.68-0.78)
<b>IFN-<math>\alpha</math>2<sub>N</sub></b>	36.2(17.0-53.4)	20.0(7.7-39.3)	0.001	0.64(0.56-0.72)
<b>sCD40L<sub>N</sub></b>	2625(1387-4815)	1434(835.8-2701)	<0.0001	0.67(0.61-0.73)
<b>MIP-1<math>\beta</math><sub>N</sub></b>	1000(418.3-2132)	1324(684.9-2699)	0.003	0.59(0.53-0.66)
<b>TGF-<math>\alpha</math><sub>N</sub></b>	20.0(12.9-31.0)	10.2(4.2-19.1)	<0.0001	0.69(0.64-0.75)
<b>MMP-2<sub>N</sub></b>	119653(75661-152183)	123161(102812-164515)	0.042	0.56(0.50-0.63)
<b>MMP-9<sub>N</sub></b>	910512(516362-1.344x10 <sup>6</sup> )	540324 (301475-899608)	<0.0001	0.69(0.63-0.75)
<b>IL-1ra<sub>Ag-N</sub></b>	241.2(69.7-1002.0)	102.2(-10.7-400.2)	0.005	0.62(0.54-0.71)
<b>*VEGF<sub>Ag-N</sub></b>	-20.9 (-102.5-0.0)	-0.0(-36.7-0.0)	0.006	0.59(0.52-0.65)
<b>IFN-<math>\gamma</math><sub>Ag-N</sub></b>	151.4(29.8-438.7)	31.1(2.6-217.8)	<0.0001	0.64(0.58-0.70)
<b>*TGF-<math>\alpha</math><sub>Ag-N</sub></b>	1.3(-1.9-7.9)	0.0(-1.6-3.1)	0.023	0.57(0.50-0.64)
<b>*MMP-9<sub>Ag-N</sub></b>	75895(-36060-289983)	19103(-81433-121961)	0.005	0.60(0.53-0.66)

69

70

71

72

73

74

75 **Supplementary Table 2: Median levels of individual analytes (pg/ml) obtained in the**  
76 **definite TB cases (n=160) and accuracies in the discriminating between definite TB and**  
77 **other respiratory diseases (n=274) regardless of HIV infection status.** Only analytes with  
78 p-values <0.05 in the Mann Whitney U test are shown. IQR= Inter-quartile range, AUC = area  
79 under the ROC curve, <sub>N</sub>= Unstimulated levels, <sub>Ag-N</sub> = antigen specific levels. \*The negative  
80 median values indicate that the value obtained in the antigen stimulated tube was lower than  
81 the value obtained in the nil tube and this phenomenon has been observed in previous studies  
82 <sup>1</sup>, #not significant; marker shown because it was one of the promising markers identified in  
83 our previous small study<sup>1</sup>.

<b>ANALYTE</b>	<b>TB (IQR)</b>	<b>ORD (IQR)</b>	<b>P-VALUE</b>	<b>AUC (95% CI)</b>
<b>VEGF<sub>N</sub></b>	102.2(0.0-221.4)	40.7(0.0-118.7)	< 0.0001	0,63 (0.58-0.69)
<b>*VEGF<sub>Ag-N</sub></b>	-25.29(-93.4-0.0)	0.0(-35.2-0.0)	0,0002	0.61(0.55-0.67)
<b>*IL-1RA<sub>Ag-N</sub></b>	173.0(31.2-596)	78.7(-33.7-361.9)	0,0052	0.61(0.54-0.68)
<b>IFN-<math>\gamma</math><sub>N</sub></b>	18.7(9.0-38.3)	5.6(1.1-14.3)	<0.0001	0.75(0.71-0.80)
<b>IFN-<math>\gamma</math><sub>Ag-N</sub></b>	140.3(27.6-353.8)	23.1(0.75-169.4)	<0.0001	0.67(0.62-0.73)
<b>IFN-A2<sub>N</sub></b>	35.2(14.0-52.3)	20.0(7.3-39.9)	0,0046	0.61(0.54-0.69)
<b>SCD40L<sub>N</sub></b>	2400(1217-4587)	1344(765.6-2611)	<0.0001	0.64(0.59-0.70)
<b>MIP-1B<sub>N</sub></b>	771.0(379.6-1737)	1289(648.5-2511)	<0.0001	0.62(0.57-0.68)
<b>TGF-A<sub>N</sub></b>	18.1(11.9-30.3)	9.8(4.2-19.1)	<0.0001	0.69(0.64-0.74)
<b>*TGF-A<sub>Ag-N</sub></b>	1.4(-1.4-7.3)	0.0(-1.8-2.9)	0,0011	0.59(0.54-0.66)
<b>MMP-9<sub>N</sub></b>	828920(491573-1.284X10 <sup>6</sup> )	508208(298606-868733)	<0.0001	0.68(0.62-0.73)
<b>MMP-9<sub>Ag-N</sub></b>	44076(-40408-242490)	4119(-84693-113762)	0,0030	0.59(0.53-0.66)
<b>#IL-1A<sub>N</sub></b>	12.5(1.2-29.7)	14.2(3.1-53.1)	0,0975	0.55(0.49-0.61)

84

85

86

87 **References**

88

- 89 1 Chegou, N. N., Black, G. F., Kidd, M., van Helden, P. D. & Walzl, G. Host markers in  
90 QuantiFERON supernatants differentiate active TB from latent TB infection:  
91 preliminary report. *BMC pulmonary medicine* **9**, 21, doi:10.1186/1471-2466-9-21  
92 (2009).  
93